biologics
Biologics Hit Multiple Targets in Asthma and COPD
The future of pulmonary medicine is rapidly evolving, with biologic therapies hitting multiple targets in asthma ...
OCTOBER 28, 2024
Advanced Therapy Combinations Show Promise in Treating IBD
Therapeutic strategies employing a combination of advanced therapies are starting to reveal promising outcomes in ...
JANUARY 17, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
DECEMBER 30, 2023
FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC
The FDA has approved a subcutaneous version of Entyvio for maintenance therapy in adults with moderate to severe ...
OCTOBER 6, 2023
Dual-Targeted Therapy in IBD Not Yet Ready for Prime Time
More evidence on the safety and efficacy of dual-targeted therapy for IBD is needed, according to presentations at ...
MARCH 22, 2023
Disconnect Between ACG/AGA Guidelines and Insurance Policies on IBD Biologics
Many major insurance companies do not adhere to the most recent recommendations on IBD treatment from the ACG and ...
MARCH 17, 2023
Study Finds Ustekinumab and Vedolizumab Equally Persistent for Crohn’s After Anti-TNFs
CHARLOTTE, N.C.—Patients with Crohn’s disease who progress from anti–tumor necrosis factor agents ...
JANUARY 19, 2023
Racial Disparities Seen in Use of IBD Medical Therapy
Black patients with IBD are less likely to be treated with certain therapies than white IBD patients, according to ...
JANUARY 17, 2023
3-Drug Regimen With 2 Biologics Deployed in High-Risk Crohn’s Trial
The combination of two monoclonal antibodies targeting different inflammatory mediators plus methotrexate was found ...
SEPTEMBER 14, 2022
Feds to Push for More Biosimilar Competition
The FDA and the FTC announced they will take further action to stem anticompetitive practices that are blocking ...
FEBRUARY 17, 2020
Study Links Psoriasis Therapy to Improved Heart Disease
Treating psoriasis with biologic drugs that target inflammation can reduce the early plaque buildup that leads to ...
FEBRUARY 14, 2019
FDA’s Dr. Gottlieb Chastises Big Pharma for Biosimilar Entry Delays
Of the 11 biosimilars approved by the FDA, only three have reached the U.S. market.
JULY 20, 2018
